Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Micro systems: the ultimate in downsizing. Interview by Bill W. Childs

¹Health Micro Data Systems, Madison, WI.

Healthcare Informatics : the Business Magazine for Information and Communication Systems

|March 10, 1991

Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Validation of PREDICT tool v2.2 in patients with early-stage breast cancer enrolled in the GIM and MIG trials.

ESMO open·2026

Same author

Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world.

ESMO open·2025

Same author

Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial.

ESMO open·2024

Same author

Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Same author

Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054].

ESMO open·2021

Same author

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI).

ESMO open·2021